Study guide
4.2 Coagulation Cascade Disorders
AMT Medical Laboratory Scientist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: General Laboratory Operations, Safety & Quality
1.1 Laboratory Safety, OSHA Standards, Hazard Communication, and Biohazard Control 1.2 Quality Systems, Quality Control, and Westgard Rules Interpretation 1.3 Specimen Collection, Handling, Order of Draw, and Phlebotomy Complications 1.4 Laboratory Instrumentation, Photometry, Spectrophotometry, and Centrifugation 1.5 Laboratory Mathematics, Dilutions, Solution Preparation, and Standard Curves 1.6 Regulatory Compliance, CLIA '88 Regulations, Accreditation, and Laboratory Ethics
2 Chapter 2: Clinical Chemistry & Metabolic Testing
2.1 Carbohydrate Metabolism, Glucose Regulation, Diabetes Mellitus, and HbA1c 2.2 Proteins, Non-Protein Nitrogenous Compounds (BUN, Creatinine, Uric Acid), and Renal Function 2.3 Enzymology and Organ Systems 2.4 Electrolytes, Acid-Base Balance, Anion Gap, and Blood Gas Analysis 2.5 Clinical Endocrinology, Thyroid, Adrenal, and Reproductive Hormones 2.6 Clinical Toxicology, Therapeutic Drug Monitoring (TDM), and Pharmacokinetics 2.7 Lipids, Lipoproteins, and the Friedewald LDL Calculation
3 Chapter 3: Hematology & Leukocyte Disorders
3.1 RBC Indices and Anemia 3.2 WBC Differential and Benign Disorders 3.3 Hematologic Malignancies 3.4 Hemoglobin Structure, Hemoglobinopathies (Sickle Cell, Thalassemia), and Variants 3.5 Hematology Automation, Flow Cytometry, and Cell Counting Technology
4 Chapter 4: Coagulation & Hemostasis
4.1 Primary and Secondary Hemostasis, Platelet Function, and Vascular Integrity 4.2 Coagulation Cascade Disorders 4.3 Coagulation Testing and Anticoagulants
5 Chapter 5: Immunology & Serology
5.1 Immune Mechanisms, Hypersensitivity Reactions, and Autoimmune Disease Testing 5.2 Serological Testing Principles and Infectious Serology
6 Chapter 6: Immunohematology & Blood Grouping
6.1 ABO and Rh Blood Group Systems, Antigens, Subgroups, and Weak D Variant 6.2 Red Cell Antibody Screening, Identification Panels, and Dosage Effects 6.3 Direct and Indirect Antiglobulin Testing (DAT/IAT) and Troubleshooting 6.4 Compatibility Testing, Crossmatching, and Hemolytic Disease of the Fetus and Newborn
7 Chapter 7: Blood Banking & Transfusion Medicine
7.1 Blood Donor Selection, Screening, Collection, and Component Storage 7.2 Transfusion Practice, Indications for Blood Components, and Administration 7.3 Transfusion Reactions: Investigation Protocol and Reaction Classification
8 Chapter 8: Clinical Microbiology
8.1 Specimen Processing, Gram Stain, and Aerobic Gram-Positive Cocci 8.2 Gram-Negative Bacilli: Enterobacteriaceae, Non-Fermenters, and Fastidious Organisms 8.3 Anaerobic Bacteria, Mycobacteria, Acid-Fast Stains, and Molecular Diagnostic Methods 8.4 Clinical Mycology and Medical Parasitology 8.5 Antimicrobial Susceptibility Testing, Resistance, and Virology
9 Chapter 9: Urinalysis & Body Fluids
9.1 Physical and Chemical Examination of Urine and Reagent Strip Principles 9.2 Microscopic Urinalysis: Cells, Casts, Crystals, and Renal Pathology 9.3 Analysis of Cerebrospinal Fluid (CSF), Serous Fluids, and Synovial Fluid
4.2 Coagulation Cascade Disorders
Key Takeaways Explain This Topic AI
Hemophilia A is an X-linked deficiency of Factor VIII, causing deep joint bleeding and a prolonged aPTT.
Hemophilia B (Christmas Disease) is an X-linked deficiency of Factor IX, clinically indistinguishable from Hemophilia A.
von Willebrand Disease (vWD) is the most common inherited bleeding disorder, presenting primarily with mucocutaneous bleeding.
vWF acts as a carrier protein for Factor VIII, protecting it from rapid degradation in the circulation.
The ristocetin cofactor assay measures vWF activity; absent agglutination indicates defective or deficient vWF.
Last updated: July 2026
Coagulation Cascade Disorders, Factor Deficiencies, and von Willebrand Disease
Coagulation disorders generally present with bleeding diatheses that can range from mild, prolonged bleeding after surgery to spontaneous, life-threatening hemorrhages into joints or intracranial spaces. These conditions can be broadly classified based on whether they affect primary hemostasis (platelet and vascular disorders) or secondary hemostasis (coagulation factor deficiencies). Understanding the pathophysiology and laboratory presentation of these disorders is essential for the Medical Laboratory Scientist.
Disorders of Secondary Hemostasis: The Hemophilias
The hemophilias are classic examples of secondary hemostasis disorders. They are characterized by deficiencies in specific coagulation factors of the intrinsic pathway, leading to defective fibrin clot formation. Because the platelet plug forms normally, patients typically do not experience immediate bleeding from superficial cuts (which is controlled by primary hemostasis). Instead, they present with delayed, deep tissue bleeding, classically into the joints (hemarthrosis) and muscles, as the unstable primary plug breaks down without the reinforcing fibrin mesh.
Hemophilia A (Factor VIII Deficiency)
Hemophilia A is an X-linked recessive disorder caused by a quantitative or qualitative deficiency in Factor VIII . It is the most common severe inherited coagulation factor deficiency, affecting approximately 1 in 5,000 male births.
In the coagulation cascade, Factor VIII acts as the essential cofactor for Factor IXa in the intrinsic tenase complex. Without sufficient Factor VIII, the intrinsic pathway cannot adequately activate Factor X, leading to severely impaired thrombin generation and defective clot formation.
Laboratory findings in Hemophilia A include:
Normal Platelet Count and Normal Prothrombin Time (PT)
Prolonged Activated Partial Thromboplastin Time (aPTT) : Because Factor VIII is part of the intrinsic pathway.
Normal von Willebrand Factor (vWF) antigen and activity .
Decreased Factor VIII activity assay .
Hemophilia B (Factor IX Deficiency)
Hemophilia B, also known as Christmas Disease, is clinically indistinguishable from Hemophilia A. It is also an X-linked recessive disorder, but it is caused by a deficiency in Factor IX . Factor IX is a vitamin K-dependent serine protease that, when activated to IXa, forms the catalytic subunit of the intrinsic tenase complex.
Laboratory findings mirror Hemophilia A exactly (prolonged aPTT, normal PT), but specific factor assays will reveal decreased Factor IX activity with normal Factor VIII activity. Both Hemophilia A and B are treated with recombinant factor replacement therapy.
von Willebrand Disease (vWD)
von Willebrand Disease is the most common inherited bleeding disorder, affecting up to 1% of the general population. It is caused by a quantitative or qualitative defect in von Willebrand Factor (vWF) . It typically inherits in an autosomal dominant pattern.
Pathophysiology of vWD
vWF serves two critical functions in hemostasis:
Primary Hemostasis : It acts as the bridge between the platelet GPIb receptor and subendothelial collagen, mediating platelet adhesion at sites of vascular injury.
Secondary Hemostasis : It acts as a carrier protein for Factor VIII in the circulation. vWF binds securely to Factor VIII, protecting it from rapid proteolytic degradation and increasing its half-life significantly.
Because of this dual role, a deficiency in vWF can impair both primary and secondary hemostasis, though the primary hemostatic defect is usually more prominent clinically. Patients typically present with mucocutaneous bleeding (epistaxis, gingival bleeding, menorrhagia) characteristic of platelet disorders, rather than the deep joint bleeding seen in hemophilia.
Types of vWD
Type 1 : The most common form (70-80% of cases). It is a partial quantitative deficiency of functionally normal vWF.
Type 2 : Qualitative defects in vWF. There are several subtypes (2A, 2B, 2M, 2N) based on the specific functional impairment, such as absent high-molecular-weight multimers or abnormal affinity for GPIb.
Type 3 : A rare, severe, virtually total quantitative absence of vWF. Because vWF is entirely absent, Factor VIII is unprotected and rapidly degraded, leading to very low Factor VIII levels and hemophilia-like bleeding symptoms in addition to severe mucocutaneous bleeding.
Laboratory Diagnosis of vWD
The initial screening tests for a bleeding disorder may show a normal or slightly prolonged aPTT (due to concurrent mild Factor VIII deficiency) and a normal PT. The platelet count is typically normal. The definitive diagnosis relies on specific vWF assays:
vWF Antigen (vWF:Ag) : Measures the total amount of vWF protein in the plasma. It is decreased in Types 1 and 3, but may be normal in Type 2.
Factor VIII Activity : Often mildly decreased, but proportional to the vWF level.
Ristocetin Cofactor Assay (vWF:RCo) : This is the classic functional assay for vWF. Ristocetin is an antibiotic that induces vWF to bind to platelet GPIb in vitro, causing the platelets to agglutinate. In vWD, this ristocetin-induced platelet aggregation is abnormally low or absent because the patient's plasma lacks functional vWF.
By analyzing the ratio of vWF activity (vWF:RCo) to vWF antigen (vWF:Ag), laboratories can differentiate between quantitative (Type 1) and qualitative (Type 2) defects.